Invesco’s Trillium Therapeutics Inc. TRIL Stock Holding History

Invesco’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-37,627	Closed	-$660K	–	4166
2021 Q3	$660K	Sell	37,627 -789,576	-95%	-$9.22M	﹤0.01%	3299
2021 Q2	$8.02M	Sell	827,203 -60,125	-7%	-$566K	﹤0.01%	2197
2021 Q1	$9.53M	Buy	887,328 +3,875	+0.4%	+$47.9K	﹤0.01%	1982
2020 Q4	$13M	Buy	883,453 +433,453	+96%	+$6.25M	﹤0.01%	1673
2020 Q3	$6.39M	Buy	+450,000	New	+$4.49M	﹤0.01%	1881

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Invesco's TRIL Position: Q4 2021 in Review

Invesco sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 37,627 shares — an estimated $660K sold.

Invesco first reported a position in TRIL in Q3 2020 and held it in 5 quarters. The position peaked at $13M in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Invesco reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Invesco sold 37,627 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $660K.
Invesco first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 5 quarters.
Invesco's Trillium Therapeutics Inc. position peaked at $13M in Q4 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Invesco's 13F filing for Q4 2021, filed 14 Feb 2022.